Ixazomib, lenalidomide, and dexamethasone combination in “real-world” clinical practice in patients with relapsed/refractory multiple myeloma

2021 ◽  
Author(s):  
Juraj Sokol ◽  
Tomas Guman ◽  
Juraj Chudej ◽  
Monika Hlebaskova ◽  
Natalia Stecova ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Clinical Practice ◽  
Real World ◽  
Refractory Multiple Myeloma

scholarly journals Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice

2018 ◽  
Vol 2 (1) ◽  
pp. e104 ◽  
Author(s):  
Cyrille Hulin ◽  
Javier de la Rubia ◽  
Meletios A. Dimopoulos ◽  
Evangelos Terpos ◽  
Eirini Katodritou ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Clinical Practice ◽  
Real World ◽  
Refractory Multiple Myeloma

Real-world treatment patterns in relapsed/refractory multiple myeloma: Clinical and economic outcomes in patients treated with pomalidomide or daratumumab

2021 ◽  
pp. 107815522199553
Author(s):  
Joshua Richter ◽  
Vamshi Ruthwik Anupindi ◽  
Jason Yeaw ◽  
Suneel Kudaravalli ◽  
Stojan Zavisic ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Real World ◽  
Treatment Options ◽  
Proteasome Inhibitors ◽  
Economic Outcomes ◽  
Office Visits ◽  
Refractory Multiple Myeloma ◽  
Kaplan Meier ◽  
Real World Evidence ◽  
New Treatment

Introduction Real-world evidence on later line treatment of relapsed/refractory multiple myeloma (RRMM) is sparse. We evaluated clinical outcomes among RRMM patients in the 1-year following treatment with pomalidomide or daratumumab and compared economic outcomes between RRMM patients and non-MM patients. Patient and Methods Adult patients with ≥1 claim of pomalidomide or daratumumab were identified between January 2012 and February 2018 using IQVIA PharMetrics® Plus US claims database. Patients were required to have a diagnosis or treatment for MM and a claim of any immunomodulatory drugs and proteasome inhibitors before the index date. Mean time to new therapy, overall survival (OS) using Kaplan-Meier curve and adverse events (AEs) were reported over the 1-year post-index period. RRMM patients were also matched to a non-MM comparator cohort and economic outcomes were compared between the two cohorts. Results 289 RRMM patients were matched to 1,445 patients without MM. Most prevalent hematological AE was anemia (72.0%) and non-hematological AE was infections (75.4%). Mean (SD) time to a new treatment was 4.7 (5.3) months and median OS was 14.6 months. RRMM patients had significantly higher hospitalizations and physician office visits (Both P < .0001) compared to non-MM patients. Adjusting for baseline characteristics, patients with RRMM had 4.9 times (95% CI 3.8-6.4, P < .0001) the total healthcare costs compared with patients without MM. The major driver of total costs among RRMM patients was pharmacy costs (67.3%). Conclusion RRMM patients showed a high frequency of AEs, low OS, and a substantial economic burden suggesting need for effective treatment options.

Real world experience with “generic” pomalidomide in relapsed refractory multiple myeloma

2018 ◽  
Vol 60 (4) ◽  
pp. 1102-1104 ◽  
Author(s):  
Aditya Jandial ◽  
Kundan Mishra ◽  
Deepesh Lad ◽  
Gaurav Prakash ◽  
Alka Khadwal ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Real World ◽  
Refractory Multiple Myeloma

Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma

2019 ◽  
Vol 64 (2) ◽  
pp. 349-355 ◽  
Author(s):  
Aleksander Salomon-Perzyński ◽  
Adam Walter-Croneck ◽  
Lidia Usnarska-Zubkiewicz ◽  
Dominik Dytfeld ◽  
Patrycja Zielińska ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Real World ◽  
Refractory Multiple Myeloma ◽  
Heavily Pretreated ◽  
Pretreated Patients
Sign in / Sign up

Export Citation Format

Share Document